Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048719 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 383
- Enrollment target
NCT05048719 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 383 participants.
The verdict
NCT05048719, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 383 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
- DRUG LY3502970
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048719
The ClinicalTrials.gov registry entry for NCT05048719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05048719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05048719 about?
NCT05048719 is a clinical study titled "A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus". The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.
What is the current status of trial NCT05048719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 383 participants. The study started on 2021-09-15. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT05048719?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG), LY3502970 (DRUG).
Who is sponsoring clinical trial NCT05048719?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.